

PRESS INFORMATION

PRESS INFORMATIONJune 29, 2018 || page 1 | 3

Optimising self-assembling molecular structures for use in diagnostics applications

Researchers from the Fraunhofer Institute for Cell Therapy and Immunology IZI, Harvard University and the University of Cambridge probing the mysteries of how DNA molecules can self-assemble into complex structures have found ways of tuning the assembly process to make it more efficient and significantly faster. It brings them closer to their goal of being able to engineer the assembly of DNA brick structures so that they could be used in applications such as diagnostics. And there are other potential applications in the fabrication of devices, such as nanoscale logic circuits and data structures, that could be the building blocks of a future ‘nano computer’.

The researchers from the Fraunhofer IZI Unit DNA Nanodevices and their Cambridge colleagues have been studying microscopic self-assembling molecular structures for some time in order to advance our understanding of the physics behind them. Their latest work has focused on DNA brick construction techniques and how they can be used to ‘print’ precise arrangements of molecules onto surfaces, for example to create large arrays that could be used in some diagnostic applications.

The researchers knew that when dealing with systems involving DNA brick structures, problems can occur. For example, it can take several days for the structures to assemble. And the yield of correctly formed structures at the end of the process can often be very low – less than one per cent. These structures are formed in systems that have thousands of distinct components and if just one molecule bonds in the wrong place, and other molecules mistakenly bond with it, it can then frustrate the growth of the target structure.

But in a paper recently published in PNAS (Proceedings of the National Academy of Sciences), the Leipzig-Cambridge team demonstrates a simple strategy for optimising the nucleation, or initial, step in the self-assembly of a multicomponent DNA brick structure. As a result, they are also able to offer some protocols for the assembly process, in order to improve the yields of structures created, from less than one per cent up to 25 per cent.

In order to understand the process, so that they could try to optimise it, the researchers used the technique of dynamic light scattering for the first time in the context of DNA self-assembly to probe the assembly process. “It worked very well, allowing us to observe the process in real time,” says Dr Aleks Reinhardt, a researcher at Cambridge University. “Other approaches, like fluorescence measurements, require us to stop the

Editor

Jens Augustin | Fraunhofer Institute for Cell Therapy and Immunology IZI | Phone +49 341 35536-9320 | Perlickstr. 1 | 04103 Leipzig | Germany | www.izi.fraunhofer.de | jens.augustin@izi.fraunhofer.de

FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY IZI

assembly process and also, the fluorescent dyes used can themselves interfere with the process. DLS is less invasive and also much more sensitive.”

PRESS INFORMATIONJune 29, 2018 || page 2 | 3

Combining that with a theoretical model they were able to show that the ultimate yield of correctly-assembled structures is largely determined by the nucleation pathway. They established some design principles for improving the self-assembly of addressable nanoscale structures. All of this work follows on from the initial discovery, made by scientists at Harvard in 2012, that potentially thousands of distinct DNA molecules can reproducibly self-assemble into complex, fully addressable and nearly error-free target structures. Making the structures ‘addressable’ – i.e. where each component is unique and in an exactly-specified position – is vitally important for constructing nanoscale devices as, by controlling their structure, scientists can control their function.

“Complexity in the world of DNA self-assembly was stuck on a huge variety of scaffold-based architectures,” explains Martin Sajfutdinow, researcher at Fraunhofer IZI and first author of the article. “The discovery of DNA bricks paved the way to carve more complex and precise structures without a scaffold, which means theoretically without any size restriction. Certainly, the system was not working optimally. In long term the project should help us to create large-size and -scale stamps for Single Molecule Contact Printing, which could be a powerful technique to cost-efficiently nanostructure surfaces in sub-10-nm level.”

The researchers at Fraunhofer IZI combined the theoretical modelling work done by their colleagues at Cambridge University with their experimental research. Over time it led to an understanding of how nucleation – the initial step in the construction process – plays a very significant role in successful DNA brick structure assembly and how it can be optimised.

As Sajfutdinow and colleagues say in their paper: “In a typical annealing protocol, structures have a limited time and temperature window in which to form: at high temperatures, a large free-energy barrier inhibits nucleation, while at low temperatures, self-assembly is limited by kinetic arrest. The key to successful self-assembly is to increase the width of the temperature window over which nucleation can occur, thereby maximizing the thermodynamic segregation between the critical nucleation step and detrimental misbonding.”

One result of being able to optimise the assembly process is that it can now be speeded up by a factor of ten, allowing structures to be assembled in a day rather than a week. It is hoped that this will stimulate experimental efforts towards developing practical applications.

Read the article Direct observation and rational design of nucleation behavior in addressable self-assembly online at: <https://doi.org/10.1073/pnas.1806010115>

FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY IZI

The Fraunhofer Institute for Cell Therapy and Immunology IZI

PRESS INFORMATION

June 29, 2018 || page 3 | 3



The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops solutions to specific problems at the interfaces of medicine, life sciences and engineering. One of the institute's main tasks is to conduct contract research for companies, hospitals, diagnostic laboratories and research institutes operating in the field of biotechnology, pharmaceuticals and medical engineering. The Fraunhofer IZI develops, optimizes and validates methods, materials and products for the business units Cell and Gene Therapy, Drugs, Diagnostics and Biosystems Technology. Its areas of competence lie in cell biology, immunology, drug biochemistry, biomarker, bioanalytics and bioproduction as well as process development and automation. In these areas, research specifically focusses on the indications oncology, neuropathology, autoimmune and inflammatory diseases as well as infectious diseases and regenerative medicine.

The **Fraunhofer-Gesellschaft** is the leading organization for applied research in Europe. Its research activities are conducted by 72 institutes and research units at locations throughout Germany. The Fraunhofer-Gesellschaft employs a staff of more than 25,000, who work with an annual research budget totaling 2.3 billion euros. Of this sum, almost 2 billion euros is generated through contract research. More than 70 percent of the Fraunhofer-Gesellschaft's contract research revenue is derived from contracts with industry and from publicly financed research projects. International collaborations with excellent research partners and innovative companies around the world ensure direct access to regions of the greatest importance to present and future scientific progress and economic development.

Further contact

Dr. David M. Smith | Phone +49 341 35536- 9311 | david.smith@izi.fraunhofer.de | Fraunhofer Institute for Cell Therapy and Immunology IZI | www.izi.fraunhofer.de/en